GoInVivo™ antibodies, validated biofunctional antibodies for immune checkpoint research
Miguel A. Tam
Friday, May 27, 2016
Tweet
Transcript
Embed
Email
Bookmark
<<
<
>
>>
Tweet
Facebook
Email
Chapters
Introduction
Immune Checkpoints
What are GoInVivo™ Antibodies?
Stringent QC Process
Anti-human CTLA-4 inhibits production of IL-2 by Jurkat cells
In vivo treatment experimental design I
CD4 T Cells expand and CD8 T Cells contract after PD-L1 treatment
Activated phenotype of CD4 T Cells after PD-L1 treatment
Activated phenotype of CD8 T Cells after PD-L1 treatment
Splenic Dendritic Cells Downregulate CD80 after PD-L1 treatment
T cells Re-distribute in PD-L1 Treated Tumor Sections
Reduced TAM in PD-L1 Treated Mice
Increased CD8+ DCs in PD-L1 Treated dLN
Chemokine and Cytokine Screening by LEGENDplex
LEGENDplex Principle
Analytes screened
Increased Th Cytokines in Serum
Decreased Pro-inflammatory Cytokines in Serum
Increased Chemokines in Serum
Cytokine and Chemokine Changes in Serum
In vivo treatment experimental design II
Slight increase of Tumor-Specific CD8+ T Cells at d10
Increased IFN-γ-producing cells at d10
Increased Specific CD8+ TIL at d24
Increased CD8α+ Tumor-associated Dendritic Cells at d24
PD-L1 injection controls tumor growth d24
Tim3 Does not affect tumor development d24
Conclusions
Acknowledgements
No transcript for this webinar
More Information
Request info